Today, we will be studying why Cara Therapeutics (CARA) is an attractive investment for 2020.
Company overview
Cara Therapeutics is a clinical-stage company focused on the development of peripheral KORs (kappa opioid receptors). The company’s lead investigational product and first-in-class KOR, Korsuva, is being explored as an injectable as well as an oral therapy for pruritus in various settings. The company has also completed a Phase 2/3 trial for Korsuva intravenous therapy in pain indication.
How do KORs work?
Four types of opioid receptors, mu, delta, kappa, and opioid-receptor like-1, play a